Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
12 Months Ended 113 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Consolidated Statements Of Operations      
Revenues         
Operating expenses:      
Amortization & depreciation 777 606 77,126
General and administrative 783,848 2,886,710 13,351,797
Total operating expenses 784,625 2,887,316 13,428,923
Loss from operations (784,625) (2,887,316) (13,428,923)
Other income (expense):      
Gain/(Loss) on fair value adjustment - derivatives 186,202 (448,137) (261,935)
Gain on sale of fixed asset    4,790 4,790
Gain on debt reversal 99,805    99,805
Interest expense (170,428) (118,194) (1,263,420)
Interest expense - beneficial conversion feature (94,161) (112,064) (276,225)
Total other income (expense) 21,418 (673,605) (1,696,985)
Loss before provision for income taxes (763,207) (3,560,921) (15,125,908)
Provision for income tax         
Net loss (763,207) (3,560,921) (15,125,908)
Less: Net loss attributable to noncontrolling interest 4,791 7,615 93,248
Net loss attributable to TranBioTec, Inc. $ (758,416) $ (3,553,306) $ (15,032,660)
Net loss per share      
(Basic and fully diluted) $ (0.02) $ (0.13)  
Weighted average number of common shares outstanding 32,540,568 28,275,127